Filed: March 9, 2016
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`————————————————
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`————————————————
`MYLAN PHARMACEUTICALS INC. and
`AMNEAL PHARMACEUTICALS LLC,
`
`Petitioners,
`
`v.
`
`YEDA RESEARCH & DEVELOPMENT CO. LTD.
`
`Patent Owner.
`————————————————
`Case IPR2015-00644
`Patent No. 8,399,413
`————————————————
`
`FOURTH UPDATED LIST OF PETITIONERS’ EXHIBITS
`
`Pursuant to 37 C.F.R. § 42.63(e), Petitioners submit the following current
`
`exhibit list.
`
`Exhibit No.
`
`1001
`
`1002
`
`1003
`
`1003A
`
`1003B
`
`1004
`
`Description
`U.S. Patent No. 8,399,413, Low Frequency Glatiramer Acetate
`Therapy (filed Aug. 19, 2010) (issued May 19, 2013)
`
`File History for U.S. Patent No. 8,399,413
`
`[Corrected] Declaration of Stephen J. Peroutka, M.D., Ph.D.
`
`Curriculum Vitae of Stephen J. Peroutka, M.D., Ph.D.
`
`Materials Reviewed by Stephen J. Peroutka, M.D., Ph.D.
`
`Expert Declaration of Ari Green, M.D.
`
`1004A
`
`Curriculum Vitae of Ari Green, M.D.
`
`
`
`1
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`————————————————
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`————————————————
`MYLAN PHARMACEUTICALS INC. and
`AMNEAL PHARMACEUTICALS LLC,
`
`Petitioners,
`
`v.
`
`YEDA RESEARCH & DEVELOPMENT CO. LTD.
`
`Patent Owner.
`————————————————
`Case IPR2015-00644
`Patent No. 8,399,413
`————————————————
`
`FOURTH UPDATED LIST OF PETITIONERS’ EXHIBITS
`
`Pursuant to 37 C.F.R. § 42.63(e), Petitioners submit the following current
`
`exhibit list.
`
`Exhibit No.
`
`1001
`
`1002
`
`1003
`
`1003A
`
`1003B
`
`1004
`
`Description
`U.S. Patent No. 8,399,413, Low Frequency Glatiramer Acetate
`Therapy (filed Aug. 19, 2010) (issued May 19, 2013)
`
`File History for U.S. Patent No. 8,399,413
`
`[Corrected] Declaration of Stephen J. Peroutka, M.D., Ph.D.
`
`Curriculum Vitae of Stephen J. Peroutka, M.D., Ph.D.
`
`Materials Reviewed by Stephen J. Peroutka, M.D., Ph.D.
`
`Expert Declaration of Ari Green, M.D.
`
`1004A
`
`Curriculum Vitae of Ari Green, M.D.
`
`
`
`1
`
`
`
`Exhibit No.
`1004B
`
`Description
`Materials Reviewed by Ari Green, M.D.
`
`Case IPR2015-00644
`Patent No. 8,399,413
`
`
`1005
`
`1006
`
`Irit Pinchasi: International Publication No. WO 2007/081975
`(published July 19, 2007)
`
`J.A. Cohen et al., Randomized, double-blind, dose-comparison
`study of glatiramer acetate in relapsing-remitting MS, 68:12
`NEUROLOGY, 939-44 (2007)
`
`1007
`
`Affidavit of Marlene S. Bobka dated December 9, 2014
`
`1007A
`
`John J. Jessop, Review and Evaluation of Pharmacology
`Toxicology Data Original NDA Review (1996) (the 1996 FDA
`SBOA) (attached as Exhibit A to Exh. 1007)
`
`1008
`
`1009
`
`1010
`
`1011
`
`Shlomo Flechter et al., Copolymer 1 (Glatiramer Acetate) in
`Relapsing Forms of Multiple Sclerosis: Open Multicenter Study
`of Alternate-Day Administration. 25:1 CLINICAL
`NEUROPHARMACOLOGY, 11-15 (2002) (Flechter 2002A)
`
`Zeev Meiner et al., Copolymer 1 in relapsing-remitting multiple
`sclerosis: a multi-centre trial, in FRONTIERS IN MULTIPLE
`SCLEROSIS: CLINICAL RESEARCH AND THERAPY (Oded
`Abramsky and Haim Ovadia, eds., 1997)
`
`Omar Khan et al., Randomized, prospective, rater-blinded,
`four-year, pilot study to compare the effect of daily versus
`every-other-day glatiramer acetate 20 mg subcutaneous
`injections in relapsing-remitting multiple sclerosis, 14
`MULTIPLE SCLEROSIS, S296 (2008)
`
`Christina Caon et al., Randomized, Prospective, Rater-Blinded,
`Four Year Pilot Study to Compare the Effect of Daily Versus
`Every Other Day Glatiramer Acetate 20 mg Subcutaneous
`Injections in RRMS, 72:11(3) NEUROLOGY, A317 (2009)
`
`2
`
`
`
`Case IPR2015-00644
`Patent No. 8,399,413
`
`
`Description
`Shlomo Flechter et al., Comparison of glatiramer acetate
`(Copaxone) and interferon β-1b (Betaferon) in multiple
`sclerosis patients: an open-label 2-year follow up, 197
`JOURNAL OF THE NEUROLOGICAL SCIENCES, 51-55 (2002).
`(“Flechter 2002B”)
`
`James R Miller, The importance of early diagnosis of multiple
`sclerosis, 10(3) (Suppl. S-b) J. MANAG. CARE PHARM., S4-11
`(2004)
`
`M.B. Bornstein, Multiple Sclerosis: Trial of a Synthetic
`Polypeptide, 11:3 ANNALS OF NEUROLOGY, 317-19 (1982)
`
`M.B. Bornstein et al., Clinical Trial of Copolymer I in Multiple
`Sclerosis, 436 ANNALS NEW YORK ACADEMY OF SCIENCES,
`366-372 (1984)
`
`M.B. Bornstein et al., A Pilot Trial of COP 1 in Exacerbating-
`Remitting Multiple Sclerosis, 317:7 THE NEW ENGLAND
`JOURNAL OF MEDICINE, 408-14 (1987)
`
`FDA, GUIDELINE FOR INDUSTRY: Dose-Response
`Information to Support Drug Registration (1994)
`
`K.P. Johnson, et al., Copolymer 1 reduces relapse rate and
`improves disability in relapsing-remitting multiple sclerosis, 43
`NEUROLOGY, 1268-1276 (1995)
`
`Exhibit No.
`
`1012
`
`1013
`
`1014
`
`1015
`
`1016
`
`1017
`
`1018
`
`1019
`
`Affidavit of Marlene S. Bobka dated January 5, 2015
`
`1019A
`
`1020
`
`1996 FDA Meeting Agenda minutes from the Peripheral and
`Central Nervous System Drug Advisory Committee (dated
`September 19, 1996) (Exhibit A to Exhibit 1019)
`Ruth Arnon, The development of Cop 1(Copaxone®), an
`innovative drug for the treatment of multiple sclerosis: personal
`reflections, 50 IMMUNOLOGY LETTERS 1-15 (1996)
`
`3
`
`
`
`Case IPR2015-00644
`Patent No. 8,399,413
`
`
`Description
`Leslie Z. Benet et al., Pharmacokinetics: The Dynamics of
`Drug Absorption, Distribution, and Elimination, in THE
`PHARMACOLOGICAL BASIS OF THERAPEUTICS, 3 (Alfred
`Goodman Gilman ed. 1996)
`
`E. Lobel, et al., Copolymer-1, 21(2) DRUGS OF THE FUTURE,
`131-134 (1996)
`
`Haines et al., Linkage of the MHC to familial multiple sclerosis
`suggests genetic heterogeneity. The multiple sclerosis genetics
`group, HUM. MOL. GENET. 7:1229-34 (Aug 1998)
`
`U.S. Patent No. 6,342,476, Copolymer-1 Improvements in
`Compositions of Copolymers (2002).
`
`Y. Ge et al., Glatiramer acetate (Copaxone) treatment in
`relapsing-remitting MS: Quantitative MR assessment, 54
`NEUROLOGY, 813-17 (2000)
`
`Giancarlo Comi et al., European/Canadian multicenter, double-
`blind, randomized, placebo-controlled study of the effects of
`glatiramer acetate on magnetic resonance imaging-measured
`disease activity and burden in patients with relapsing multiple
`sclerosis: European/Canadian Glatiramer Acetate Study
`Group, 49:3 ANN. NEUROL., 290-97 (2001)
`
`Boissel and Nony, Using pharmacokinetic-pharmacodynamic
`relationships to predict the effect of poor compliance, CLIN.
`PHARMACOL. 41:1-6 (2002)
`
`Exhibit No.
`
`1021
`
`1022
`
`1023
`
`1024
`
`1025
`
`1026
`
`1027
`
`1028
`
`McBride, INT’L J. MS CARE 4:85 (2002)
`
`1029
`
`1030
`
`Dene Simpson, Adis Drug Evaluation Glatiramer Acetate – A
`Review of its use in Relapsing-Remitting Multiple Sclerosis,
`16:12 CNS DRUGS, 825-50, 834 (2002)
`
`Catherine M. Edgar, et al., Lipoatrophy in Patients with
`Multiple Sclerosis on Glatiramer Acetate, 31 CAN. J. NEUROL.
`SCI., 58-63 (2004)
`
`4
`
`
`
`Exhibit No.
`
`1031
`
`1032
`
`1033
`
`1034
`
`1035
`
`1036
`
`1037
`
`1038
`
`1039
`
`1040
`
`Case IPR2015-00644
`Patent No. 8,399,413
`
`
`Description
`Rich et al., Stepped-care approach to treating MS: A managed
`care treatment algorithm, J. MANAGED CARE PHARM. 10:S26-
`S32 (June 2004)
`
`Stuart, Clinical management of multiple sclerosis: The
`treatment paradigm and issues of patient management, J.
`MANAGED CARE PHARMACY 10:S19-S25 (June 2004)
`
`Rohit Bakshi et al., Imaging of Multiple Sclerosis: Role in
`Neurotherapeutics, 2(2) NEURORX, 277–303 (2005)
`
`Paul Beringer et al., Clinical Pharmacokinetics and
`Pharmacodynamics, in REMINGTON: THE SCIENCE AND
`PRACTICE OF PHARMACY, 1191-1205, 1197, 1201 (Paul
`Beringer ed., 2005)
`
`Michael Franklin et al., Drug Absorption, Action, and
`Disposition, in REMINGTON: THE SCIENCE AND PRACTICE OF
`PHARMACY, 1142-1170, 1167 (Paul Beringer ed., 2005)
`
`James Rasmussen: International Patent Publication No. WO
`2005/120542 A2 (published December 22, 2005)
`
`Devonshire et al., The Global Adherence Project – A
`multicentre observational study on adherence to disease-
`modifying therapies in patients suffering from relapsing-
`remitting multiple sclerosis, MULTIPLE SCLEROSIS 12:S1 (P316)
`(2006)
`
`C.C. Ford et al., A prospective open-label study of glatiramer
`acetate: over a decade of continuous use in multiple sclerosis
`patients, 12 MULTIPLE SCLEROSIS, 309-320 (2006)
`
`Frohman, Multiple Sclerosis – The Plaque and its Pathogenesis,
`NEW ENGLAND J. MED. 354:942-55 (2006)
`
`J.J. Kragt et al., How similar are commonly combined criteria
`for EDSS progression in multiple sclerosis?, 12(6) MULTIPLE
`SCLEROSIS782-786 (2006)
`
`5
`
`
`
`Case IPR2015-00644
`Patent No. 8,399,413
`
`
`Description
`Peter J. Manso et al., Life cycle management of ageing
`pharmaceutical assets, 3:7 PHARMACEUTICAL LAW INSIGHT,
`(2006)
`
`Soares et al., Localized panniculitis secondary to subcutaneous
`glatiramer acetate injections for the treatment of multiple
`sclerosis: a clinicopathologic and immunohistochemical study,
`J. AM. ACAD. DERM. 55:968-74 (2006)
`
`Klauer and Zettl, Compliance, adherence and the treatment of
`multiple sclerosis, J. NEUROL. 255 [Suppl. 6]:87-92 (2008)
`
`Pelidou et al., Multiple sclerosis presented as clinically isolated
`syndrome: the need for early diagnosis and treatment, THER.
`CLIN. RISK MANAGEMENT 4:627-30 (June 2008)
`
`Tjalf Ziemssen et al., Effects of glatiramer acetate on fatigue
`and days of absence from work in first-time treated relapsing-
`remitting multiple sclerosis, 6 HEALTH AND QUALITY OF LIFE
`OUTCOMES 67 (2008)
`
`Teva Provides Update on Forte Trial Jerusalem, Israel
`(July 7, 2008)
`Copaxone® U.S. Product Label (2001)
`Betaseron® U.S. Product Label (2003)
`Rebif® U.S. Product Label (2003)
`Avonex® Product Label (2006)
`Tysabri® Product Label (2008)
`Copaxone® U.S. Product Label (Feb. 2009)
`Extavia® Product Label (2009)
`
`Exhibit No.
`
`1041
`
`1042
`
`1043
`
`1044
`
`1045
`
`1046
`
`1047
`
`1048
`
`1049
`
`1050
`
`1051
`
`1052
`
`1053
`
`6
`
`
`
`Exhibit No.
`
`1054
`
`1055
`
`1056
`
`1057
`
`1058
`
`1059
`
`1060
`
`1061
`
`1062
`
`1065
`
`1066
`
`1067
`
`1068
`
`Case IPR2015-00644
`Patent No. 8,399,413
`
`
`Description
`Jacobs et al., Intramuscular interferon beta-1a therapy initiated
`during a first demyelinating event in multiple sclerosis, NEW
`ENGL. J. MED 343:898-904 (2000) (“Jacobs”)
`
`Stedman’s Medical Dictionary for Health Professionals (2008)
`
`U.S. Patent Publication No. 2009/0149541A1 (filed Nov. 26,
`2008)
`
`Concepts in clinical pharmacokinetics, in INTRODUCTION TO
`PHARMACOKINETICS AND PHARMACODYNAMICS, Tozer and
`Rowland eds (Lippincott Williams & Wilkins 2006)
`
`M. Tintore et al., Baseline MRI predicts future attacks and
`disability in clinically isolated syndromes, 67 NEUROLOGY 968-
`972, (2006).
`
`FDA GUIDANCE FOR INDUSTRY - POPULATION
`PHARMACOKINETICS (1999)
`
`REBIF® Product Label (June 2005)
`
`http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.
`cfm?Appl_No=020622&Product_No=003&table1=OB_Rx
`(accessed February 5, 2015)
`
`https://scamparoo.wordpress.com/2008/04/11/ms-therapies-
`copaxone/ (dated April 11, 2008 (accessed February 5, 2015))
`
`October 22, 2015 Deposition of Dr. Ari Green
`
`October 29, 2015 Deposition of Dr. Stephen Peroutka
`
`Petitioners’ Notice of Deposition of Dr. Edward J. Fox
`
`O. Khan, et al., Glatiramer acetate 20mg subcutaneous twice -
`weekly versus daily injections: results of a pilot, prospective,
`randomised, and rater-blinded clinical and MRI 2-year study in
`relapsing-remitting multiple sclerosis, MULTIPLE SCLEROSIS
`2009; 15:S151-S269, S249-S250 (2009)
`
`7
`
`
`
`Exhibit No.
`
`1069
`
`1070
`
`1071
`
`1072
`
`1073
`
`1074
`
`1075
`
`1076
`
`1077
`
`1078
`
`1079
`
`Case IPR2015-00644
`Patent No. 8,399,413
`
`
`Description
`G. Pardo, et al., Impact of an oral antihistamine on local
`injection site reactions with glatiramer acetate, MULTIPLE
`SCLEROSIS, 2007; 13:S7-S2753, S134 (2007)
`
`S. Bains, et al., Glatiramer acetate: successful desensitazation
`for treatment of multiple sclerosis, ANNALS OF ALLERGY,
`ASTHMA & IMMUNOLOGY, 2010;104:321-325.
`
`E. Fisher, et al., Gray Matter Atrophy in Multiple Sclerosis: A
`Longitudinal Study, ANNALS OF NEUROLOGY, 2008;64:255-265
`
`Fourth Declaration of Edward J. Fox, M.D., Ph.D., In re
`Copaxone 40 mg Consolidated Cases, Civil Action No. 1:14-
`cv-001171, ECF No. 155 (D. Del.)
`
`G. Anderson, et al., Tolerability and safety of novel half
`milliliter formulation of glatiramer acetate for subcutaneous
`injection: an open-label, multicenter, randomized comparative
`study, JOURNAL OF NEUROLOGY (2010) 257:1917-1923
`
`G. Shaw, Exorbitant Drug Costs May Price Out Patients, THE
`WASHINGTON DIPLOMAT (April 27, 2011).
`
`Letter, Mitrokostas to White dated January 19, 2016
`
`Stipulated Protective Order in In re Copaxone 40 mg
`Consolidated Cases, No. 1:14-cv-01171 (GMS) (entered by
`minute entry on May 27, 2015)
`
`Jazz Pharmaceuticals Inc. v. Amneal Pharmaceuticals LLC et
`al., No. 2:13-cv-00391, Order January 22, 2016
`
`Transcript of January 21, 2016 Teleconference
`
`T. Ziemssen, et al., A 2-year observational study of patients
`with relapsing-remitting multiple sclerosis converting to
`glatiramer acetate from other disease-modifying therapies: the
`COPTIMIZE trial, JOURNAL OF NEUROLOGY (2014) 261:2101–
`2111
`
`8
`
`
`
`Exhibit No.
`
`1080
`
`1081
`
`1082
`
`1083
`
`1084
`
`1085
`
`1086
`
`1087
`
`Case IPR2015-00644
`Patent No. 8,399,413
`
`
`Description
`T. Ziemssen, et al., Sub-analysis of geographical variations
`inthe 2-year observational COPTIMIZE trial of patients with
`relapsing–remitting multiple sclerosis converting to glatiramer
`acetate, BMC NEUROLOGY (2015) 15:189
`
`T. Ziemssen, et al., QualiCOP: An Open-Label, Prospective,
`Observational Study of Glatiramer Acetate in Patients with
`Relapsing-Remitting Multiple Sclerosis
`
`N. Kleiner, et al., Immunological Response to Glatiramer
`Acetate in MS Patients after Different Pretreatments – The
`CopImmunoNet Study, P06.178, A554 NEUROLOGY 74, Suppl 2
`(March 2, 2010)
`
`Teva News Release, New Study Demonstrated Significant
`Reduction in Annualized Relapse Rate and Halting of Disability
`Progression in MS Patients Switching to Copaxone® (April 14,
`2011)
`
`R. Aharoni, et al., Glatiramer acetate-specific T cells in the
`brain express T helper 2/3 cytokines and brain-derived
`neurotrophic factor in situ, PNAS 100(24):14157-14162
`(November 25, 2003)
`
`Expert Declaration of Ari Green, M.D. in Support of
`Petitioner’s Reply to Patent Owner’s Response
`
`Teva’s Shared Solutions® How to Prepare for Your Injection,
`http://www.copaxone.com/injection-assistance/preparing-your-
`injection.html (last visited Mar. 7, 2016)
`
`Louise Gagnon, Every-Other-Day Dosing of Glatiramer
`Acetate Reduces Adverse Reactions with Comparable Efficacy
`to Daily Dosing: Presented at WCTRMS, PEERVIEW PRESS,
`Sept. 21, 2008, http://www.peerviewpress.com/every-other-
`day-dosing-glatiramer-acetate-reduces-adverse-reactions-
`comparable-efficacy-daily-dosing-presented-wctrms (last
`visited Mar. 8, 2016)
`
`9
`
`
`
`Exhibit No.
`
`1088
`
`1089
`
`1090
`
`1091
`
`1092
`
`1093
`
`1094
`
`1095
`
`1096
`
`Case IPR2015-00644
`Patent No. 8,399,413
`
`
`Description
`J. Wolinsky, Glatiramer acetate for the treatment of multiple
`sclerosis, EXPERT OPINION ON PHARMACOTHERAPY, 5(4):875–
`891 (2004) (“Wolinsky 2004”)
`
`O. Khan et al., Glatiramer acetate 20mg subcutaneous twice-
`weekly versus daily injections: results of a pilot, prospective,
`randomised, and rater-blinded clinical and MRI 2-year study in
`relapsing-remitting multiple sclerosis, MULTIPLE SCLEROSIS,
`15:S151–S269 (2009) (“Khan 2009”)
`
`M.S. Weber et al., Mechanism of Action of Glatiramer Acetate
`in Treatment of Multiple Sclerosis, NEUROTHERAPEUTICS,
`4(4):647–653 (2007) (“Weber”)
`
`W.F. Hickey et al., T-Lymphocyte Entry Into the Central
`Nervous System, J. OF NEUROSCIENCE RESEARCH, 28(2):254–
`260 (1991) (“Hickey 1991B”)
`
`T.M. Stewart et al., Injectable Multiple Sclerosis medications:
`A Patient Survey of Factors Associated with Injection-Site
`Reactions, INT’L J. MS CARE, 14(1):46–53 (2012)
`
`U.S. Dep’t Health & Human Servs., Common Terminology
`Criteria for Adverse Events (CTCAE) (Version 4.03 June 14,
`2010)
`
`B. Singer et al., Comparative injection-site pain and tolerability
`of subcutaneous serum-free formulation of interferonβ-1a
`versus subcutaneous interferonβ-1b: results of the randomized,
`multicenter, Phase IIIb REFORMS study, BMC NEUROLOGY,
`12:154 (2012)
`
`L. McEwan et al., Best Practices in Skin Care for the Multiple
`Sclerosis Patient Receiving Injectable Therapies, INT’L J. MS
`CARE, 12:177–189 (2010)
`
`R. Bermel et al., The measurement and clinical relevance of
`brain atrophy in multiple sclerosis, LANCET NEUROL.,
`5(2):158–70 (2006)
`
`10
`
`
`
`Case IPR2015-00644
`Patent No. 8,399,413
`
`
`Description
`E. Fisher et al., Gray Matter Atrophy in Multiple Sclerosis: A
`Longitudinal Study, ANN. NEUROL., 4:255–265 (2008)
`
`Lauren LeBano, Gray Matter Atrophy May Serve as an
`Effective Outcome measure for MS Clinical Trials, NEUROL.
`REVIEWS, 20(2):8 (2012)
`
`Exhibit No.
`
`1097
`
`1098
`
`1099
`
`Declaration of Prof. Joel W. Hay
`
`1100
`
`1101
`
`1102
`
`1103
`
`1104
`
`1105
`
`Xinke Zhang et al., Cost Effectiveness of Fingolimod,
`Teriflunomide, Dimethyl Fumarate and Intramuscular
`Interferon-β1a in Relapsing-Remitting Multiple Sclerosis, 29(1)
`CNS DRUGS 71 (2015)
`
`Xinke Zhang & Joel W. Hay, Cost-effectiveness of Fingolimod,
`Teriflunomide, Dimethyl Fumarate and Intramuscular
`Interferon Beta-1a in Relapsing-remitting Multiple Sclerosis,
`Poster, Monday Morning, PND20, ISPOR 19th Annual
`International Conference, May 2014, Montreal, Quebec,
`Canada
`
`Xinke Zhang & Joel W. Hay, Cost-effectiveness of Fingolimod,
`Teriflunomide, Dimethyl Fumarate and Intramuscular
`Interferon Beta-1a in Relapsing-remitting Multiple Sclerosis,
`American Society for Health Economics 5th Biennial
`Conference, June 2014, Los Angeles, CA
`
`Matthew Herper, Inside The Secret World of Drug Company
`Rebates, FORBES PHARMA & HEALTHCARE (May 10, 2012),
`http://www.forbes.com/sites/matthewherper/2012/05/10/why-
`astrazeneca-gives-insurers-60-discounts-on-nexiums-list-
`price/#155191dd4fd6
`
`Thomas Reinke, MS Drug Going Generic Without Making
`Waves, MANAGED CARE (June 2015), http://bit.ly/1KcyXdE
`
`Carly Helfand, Why is Novartis’ Copaxone copy lagging? It's
`all about coverage, analyst explains, FIERCE PHARMA (Sept. 11,
`2015), http://bit.ly/1ia8BNM
`
`11
`
`
`
`Exhibit No.
`
`1106
`
`1107
`
`1108
`
`1109
`
`1110
`
`1111
`
`1112
`
`1113
`
`1114
`
`1115
`
`1116
`
`Case IPR2015-00644
`Patent No. 8,399,413
`
`
`Description
`3-Times-A-Week Copaxone® 40 MG, TEVA,
`https://www.copaxone.com/about-copaxone/copaxone-40-mg
`
`Biogen Press Release, Biogen 2015 Revenues Increase 11% to
`$10.8 Billion (Jan. 27, 2016), BIOGEN.COM,
`http://bit.ly/1OXIl1x
`
`A to Z of MS Alemtuzumab (Lemtrada), MULTIPLE SCLEROSIS
`TRUST, http://bit.ly/1YnIfHQ
`
`R. Osborne, Buzz around Campath proof-of-concept trial in
`MS, 27(1) NATURE BIOTECHNOLOGY 6 (2009)
`
`J. A. Cohen et al., Alemtuzumab versus interferon beta 1a as
`first-line treatment for patients with relapsing-remitting
`multiple sclerosis: a randomized controlled phase 3 trial, 380
`LANCET, 3801819 (2012)
`
`IMS INSTITUTE FOR HEALTH INFORMATICS, MEDICINE USE AND
`SHIFTING COSTS OF HEALTHCARE, Chart Notes (April 2014)
`
`IMS INSTITUTE FOR HEALTH INFORMATICS, DECLINING
`MEDICINE USE AND COSTS: FOR BETTER OR WORSE?, Chart
`Notes (May 2013)
`
`Valeant Pharms. Int’l, Inc., Transcript of June 17, 2014 Investor
`Presentation, http://1.usa.gov/21PTRZK
`
`Brian Orelli, Momenta Slowed (Temporarily), THE MOTLEY
`FOOL (Nov. 7, 2015), http://bit.ly/1YiNNmS
`
`Carly Helfand, The top 10 best-selling multiple sclerosis drugs
`of 2013, FIERCEPHARMA (Sept. 9, 2014), http://bit.ly/1UKrlDd
`
`Tracy Staton, Sanofi tags newly OK’d MS drug Lemtrada at
`$158K, ready to tout head-to-head Rebif data,
`FIERCEPHARMAMARKETING (Nov. 17, 2014),
`http://bit.ly/1QDkTIZ
`
`12
`
`
`
`Case IPR2015-00644
`Patent No. 8,399,413
`
`
`Description
`Kim Frick et al., Serono to sell Amgen multiple sclerosis drug
`[Novantrone] in U.S., FIRSTWORD PHARMA (Nov. 13, 2002),
`http://bit.ly/1QXqhpR
`
`Christopher Luzzio & B. Mark Keegan, Multiple Sclerosis
`Medication, MEDSCAPE REFERENCE (Nov. 24, 2014),
`http://emedicine.medscape.com/article/1146199-medication#1
`
`MOMENTUMMAGAZINEONLINE.COM, 10 DISEASE-MODIFYING
`TREATMENTS, Nov. 2013, available at http://bit.ly/1eVa0jT.
`
`IMS Health, U.S. Pharmaceutical Market: Trends Issues &
`Outlook (Sept. 15, 2013)
`
`Jesse David & Marion B. Stewart, Commercial Success:
`Economic Principles Applied to Patent Litigation, in ECONOMIC
`DAMAGES IN INTELLECTUAL PROPERTY: A HANDS-ON GUIDE TO
`LITIGATION 159 (Daniel Slottje ed., John Wiley & Sons, Inc.
`2006)
`
`Angela Maas, New Copaxone Formulation Could Help Teva
`Retain Market Share, AIS HEALTH, Feb. 19, 2014,
`http://bit.ly/21POaLm
`
`MISSOURI DEP’T OF SOC. SERVS., SPECIALTY MAXIMUM
`ALLOWABLE COST (MAC) (Mar. 1, 2016),
`http://dss.mo.gov/mhd/cs/pharmacy/pdf/macspec.pdf
`
`Gina Shaw, Glatopa Is Strong Out of the Gate, SPECIALTY
`PHARMACY CONTINUUM (July 22, 2015), http://bit.ly/1p8U4Gb
`
`DAVID RISINGER ET AL., MORGAN STANLEY ANALYST REPORT:
`TEVA PHARMACEUTICAL INDUSTRIES LTD. (Mar. 14, 2014)
`
`Financial Support, Copaxone, TEVA,
`https://www.copaxone.com/shared-solutions/copaxone-savings-
`and-benefits (accessed Dec. 28, 2015)
`
`Exhibit No.
`
`1117
`
`1118
`
`1119
`
`1120
`
`1121
`
`1122
`
`1123
`
`1124
`
`1125
`
`1126
`
`13
`
`
`
`Exhibit No.
`
`1127
`
`1128
`
`1129
`
`1130
`
`1131
`
`1132
`
`1133
`
`1134
`
`Case IPR2015-00644
`Patent No. 8,399,413
`
`
`Description
`Copaxone, TEVA, https://www.copaxone.com (accessed Jan. 8,
`2016)
`
`Emerging Therapies Collaborative, Organization Disclosures,
`MS COALITION, http://www.ms-
`coalition.org/emergingtherapies/disclosures/organization-
`disclosures (accessed Mar. 6, 2016)
`
`Alisa Woods, The Costs of Multiple Sclerosis Treatment,
`EVERYDAY HEALTH (Feb. 22, 2016),
`http://www.everydayhealth.com/multiple-
`sclerosis/treatment/costs-of-ms-treatment/
`
`Geeta Anand, Through Charities, Drug Makers Help People –
`and Themselves, WALL ST. J. (Dec. 1, 2005),
`http://www.wsj.com/articles/SB113339802749110822
`
`Malcolm Gladwell, High Prices: How to think about
`prescription drugs, NEW YORKER (Oct. 25, 2004),
`http://www.newyorker.com/magazine/2004/10/25/high-prices
`(accessed Feb. 28, 2016)
`
`Ernst R. Berndt et al., An Analysis of the Diffusion of New
`Antidepressants: Variety, Quality, and Marketing Efforts, 5(1)
`J. OF MENTAL HEALTH POL’Y AND ECONS. 3 (2002)
`
`Ernst R. Berndt et al., Information, marketing, and pricing in
`the U.S. antiulcer drug market, 85(2) AM. ECON. REV. 100
`(1995)
`
`FDA approves new MS treatment regimen developed at Wayne
`State University by Dr. Omar Khan, DIVISION OF RESEARCH -
`RESEARCH@WAYNE,
`https://research.wayne.edu/rwnews/article.php?id=1319 (last
`visited Mar. 8, 2016)
`
`1135
`
`Pinchasi prosecution history
`
`14
`
`
`
`Case IPR2015-00644
`Patent No. 8,399,413
`
`
`Description
`Order Construing the Terms of U.S. Patent Nos. 8,232,250,
`8,399,413, 8,969,302, and 9,155,776, In Re Copaxone 40 mg
`Consolidated Cases, No. 14-1171-GMS (consolidated) (D. Del.
`Mar. 7, 2016), ECF No. 214
`
`Stipulation and [Proposed] Order Concerning Claim
`Construction Dispute, In Re Copaxone 40 mg Consolidated
`Cases, No. 14-1171-GMS (consolidated) (D. Del. Feb. 12,
`2016), ECF No. 194
`
`Transcript of Trial Testimony, Teva Pharms. USA, Inc. v.
`Sandoz, Inc., No. 1:09-cv-08824 (S.D.N.Y. Sept. 7, 2011), ECF
`No. 205
`
`Ampyra Prescribing Information, ACORDA THERAPEUTICS (Dec.
`2014)
`
`Exhibit No.
`
`1136
`
`1137
`
`1138
`
`1139
`
`
`
`Dated: March 9, 2016
`
`
`
`
`
`
`
`
`
`/Brandon M. White/
`Brandon M. White
`Reg. No. 52,354
`
`PERKINS COIE LLP
`700 13th Street, NW, Suite 600
`Washington, D.C. 20005
`Telephone: (202) 654-6204
`Facsimile: (202) 654-6211
`Email: bmwhite@perkinscoie.com
`
`Attorney for Mylan Pharmaceuticals Inc.
`
`15
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that the foregoing Fourth Updated List of
`
`Petitioners’ Exhibits was served electronically via email as follows:
`
`Patent Owners:
`
`
`Elizabeth Holland
`Goodwin Procter LLP
`eholland@goodwinprocter.com
`
`William James
`Goodwin Procter LLP
`wjames@goodwinprocter.com
`
`Eleanor Yost
`Goodwin Procter LLP
`eyost@goodwinprocter.com
`
`Nicholas Mitrokostas
`Goodwin Procter LLP
`nmitrokostas@goodwinprocter.com
`
`Daryl Wiesen
`Goodwin Procter LLP
`dwiesen@goodwinprocter.com
`
`John Bennett
`Goodwin Procter LLP
`jbennett@goodwinprocter.com
`
`
`Petitioner Amneal Pharmaceuticals, LLC:
`
`
`Vincent L. Capuano
`Duane Morris LLC
`VCapuano@duanemorris.com
`
`Christopher S. Kroon
`Duane Morris LLC
`CSKroon@duanemorris.com
`
`
`Dated: March 9, 2016
`
`
`
`
`
`
`
`/Brandon M. White/
`Brandon M. White
`
`Attorneys for Mylan Pharmaceuticals Inc.
`
`
`
`
`
`1
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
